Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mahrukh

Showing results (511-520 of 560) with videos related to

Pageof 56
Sort By:
The Lancet. Oncology|February 15, 2021
Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation studyMahrukh M Syeda, Jennifer M Wiggins, Broderick C Corless, et al.
European Urology|April 26, 2026
Comprehensive Genomic and Transcriptomic Characterization of Matched Primary and Recurrent Tumors in High-risk Localized Renal Cell CarcinomaWenxin Xu, Brian I Rini, Laurence Albiges, et al.
European Urology|July 14, 2020
Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical TrialBrian I Rini, Robert J Motzer, Thomas Powles, et al.
The Lancet. Oncology|April 18, 2025
Clinical validation of droplet digital PCR assays in detecting BRAF<sup>V600</sup>-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trialMahrukh M Syeda, Georgina V Long, James Garrett, et al.
JAMA Oncology|December 23, 2021
Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell CarcinomaRobert J Motzer, Thomas Powles, Michael B Atkins, et al.
Lancet (London, England)|September 13, 2022
Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trialSumanta Kumar Pal, Robert Uzzo, Jose Antonio Karam, et al.
The Journal of Infectious Diseases|September 28, 2018
Cutaneous Viral Infections Across 2 Anatomic Sites Among a Cohort of Patients Undergoing Skin Cancer ScreeningDana E Rollison, Michael J Schell, Neil A Fenske, et al.
Clinical Lung Cancer|January 16, 2026
Optimizing Tarlatamab Delivery in Small Cell and Neuroendocrine Lung Cancer: Real-World Insights into Step-Up Dosing and Prophylactic Tocilizumab UseUtsav Joshi, Faustine Ong, Daniel Melzer, et al.
Lancet (London, England)|June 8, 2023
Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trialSumanta Kumar Pal, Laurence Albiges, Piotr Tomczak, et al.
Cancer Cell|November 6, 2020
Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis BlockadeRobert J Motzer, Romain Banchereau, Habib Hamidi, et al.
Pageof 56

Showing results (511-520 of 560) with videos related to

Sort By:
Pageof 56
The Lancet. Oncology|February 15, 2021
Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation studyMahrukh M Syeda, Jennifer M Wiggins, Broderick C Corless, et al.
European Urology|April 26, 2026
Comprehensive Genomic and Transcriptomic Characterization of Matched Primary and Recurrent Tumors in High-risk Localized Renal Cell CarcinomaWenxin Xu, Brian I Rini, Laurence Albiges, et al.
European Urology|July 14, 2020
Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical TrialBrian I Rini, Robert J Motzer, Thomas Powles, et al.
The Lancet. Oncology|April 18, 2025
Clinical validation of droplet digital PCR assays in detecting BRAF<sup>V600</sup>-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trialMahrukh M Syeda, Georgina V Long, James Garrett, et al.
JAMA Oncology|December 23, 2021
Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell CarcinomaRobert J Motzer, Thomas Powles, Michael B Atkins, et al.
Lancet (London, England)|September 13, 2022
Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trialSumanta Kumar Pal, Robert Uzzo, Jose Antonio Karam, et al.
The Journal of Infectious Diseases|September 28, 2018
Cutaneous Viral Infections Across 2 Anatomic Sites Among a Cohort of Patients Undergoing Skin Cancer ScreeningDana E Rollison, Michael J Schell, Neil A Fenske, et al.
Clinical Lung Cancer|January 16, 2026
Optimizing Tarlatamab Delivery in Small Cell and Neuroendocrine Lung Cancer: Real-World Insights into Step-Up Dosing and Prophylactic Tocilizumab UseUtsav Joshi, Faustine Ong, Daniel Melzer, et al.
Lancet (London, England)|June 8, 2023
Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trialSumanta Kumar Pal, Laurence Albiges, Piotr Tomczak, et al.
Cancer Cell|November 6, 2020
Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis BlockadeRobert J Motzer, Romain Banchereau, Habib Hamidi, et al.
Pageof 56